Goldman Sachs
NGNE icon

Goldman Sachs’s Neurogene NGNE Stock Holding History

Goldman Sachs’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.17M Sell
107,714
-54,304
-34% -$1.05M ﹤0.01% 4465
2025
Q4 		$3.34M Buy
162,018
+89,216
+123% +$2.22M ﹤0.01% 4126
2025
Q3 		$1.26M Buy
72,802
+55,506
+321% +$1.11M ﹤0.01% 4870
2025
Q2 		$259K Sell
17,296
-3,880
-18% -$60.9K ﹤0.01% 5527
2025
Q1 		$248K Sell
21,176
-16,882
-44% -$293K ﹤0.01% 5543
2024
Q4 		$870K Sell
38,058
-3,107
-8% -$116K ﹤0.01% 4909
2024
Q3 		$1.73M Buy
41,165
+28,110
+215% +$1.09M ﹤0.01% 4275
2024
Q2 		$475K Sell
13,055
-61,032
-82% -$2.15M ﹤0.01% 4862
2024
Q1 		$3.77M Buy
+74,087
New +$2.47M ﹤0.01% 3355
2022
Q4 		– Sell
-787
Closed -$10K – 6174
2022
Q3 		$10K Sell
787
-1,201
-60% -$24.5K ﹤0.01% 6022
2022
Q2 		$41K Sell
1,988
-1,351
-40% -$33K ﹤0.01% 6066
2022
Q1 		$126K Buy
3,339
+1,044
+45% +$60.9K ﹤0.01% 6034
2021
Q4 		$222K Sell
2,295
-3,588
-61% -$437K ﹤0.01% 5837
2021
Q3 		$850K Sell
5,883
-4,553
-44% -$697K ﹤0.01% 4876
2021
Q2 		$1.93M Sell
10,436
-6,491
-38% -$1.44M ﹤0.01% 4232
2021
Q1 		$4.17M Buy
16,927
+15,506
+1,091% +$3.96M ﹤0.01% 3305
2020
Q4 		$400K Buy
1,421
+876
+161% +$214K ﹤0.01% 4742
2020
Q3 		$131K Buy
+545
New +$132K ﹤0.01% 5025
2020
Q2 		– Sell
-5,376
Closed -$1.22M – 5392
2020
Q1 		$1.22M Buy
5,376
+4,611
+603% +$949K ﹤0.01% 3624
2019
Q4 		$189K Buy
+765
New +$76.2K ﹤0.01% 4910
2018
Q4 		– Sell
-1,315
Closed -$77K – 5522
2018
Q3 		$77K Buy
+1,315
New +$77.6K ﹤0.01% 5209
2018
Q2 		– Sell
-528
Closed -$149K – 5881
2018
Q1 		$149K Sell
528
-40,041
-99% -$11.1M ﹤0.01% 5139
2017
Q4 		$9.54M Sell
40,569
-7,588
-16% -$1.78M ﹤0.01% 2484
2017
Q3 		$13.7M Buy
48,157
+12
+0% +$3.44K ﹤0.01% 2300
2017
Q2 		$13.5M Sell
48,145
-247
-0.5% -$70.7K ﹤0.01% 2273
2017
Q1 		$16.2M Sell
48,392
-49
-0.1% -$17.2K ﹤0.01% 2042
2016
Q4 		$16M Sell
48,441
-1,139
-2% -$306K ﹤0.01% 2110
2016
Q3 		$13.2M Buy
49,580
+1,722
+4% +$347K ﹤0.01% 2225
2016
Q2 		$6.34M Sell
47,858
-658
-1% -$105K ﹤0.01% 2674
2016
Q1 		$8.56M Buy
48,516
+47,614
+5,279% +$9.26M ﹤0.01% 2342
2015
Q4 		$225K Buy
+902
New +$237K ﹤0.01% 5603

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Goldman Sachs's NGNE Position: Q1 2026 in Review

Goldman Sachs reduced its Neurogene (NGNE) stake by 34% in Q1 2026, selling an estimated $1.05M and leaving 107,714 shares worth $2.17M. The position accounts for ﹤0.01% of the portfolio, ranked #4465.

Goldman Sachs first reported a position in NGNE in Q4 2015 and has held it in 31 quarters since. The position peaked at $16.2M in Q1 2017. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Goldman Sachs held 107,714 shares of Neurogene worth $2.17M as of Q1 2026.
  • Goldman Sachs sold 54,304 Neurogene shares in Q1 2026, an estimated $1.05M.
  • Neurogene made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #4465 holding.
  • Goldman Sachs first reported a position in Neurogene in Q4 2015 and has held it in 31 quarters since.
  • Goldman Sachs's Neurogene position peaked at $16.2M in Q1 2017.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.